Company: TAK
Filing Date: 2025-06-25
Form Type: F-3ASR
Source: 0001395064-25-000097
Chunk: 4

Company: TAKEDA PHARMACEUTICAL CO LTD
Filing Date: 2025-06-25
Form: F-3ASR
Chunk 4
---
 prospectus supplement and any related free writing prospectus that the relevant issuer authorizes to be delivered to you together with additional information described under the heading “Where You Can Find More Information” in this prospectus before purchasing any of our securities.

The terms “Takeda” and the “Company” refer to Takeda Pharmaceutical Company Limited and, unless the context requires otherwise, its consolidated subsidiaries, including TUSFI. The term “TPC” refers to Takeda Pharmaceutical Company Limited on a standalone basis as the issuer of senior debt securities or as the guarantor of senior debt securities issued by TUSFI, as the context may require. The term “TUSFI” refers to Takeda U.S. Financing, Inc. Each of TPC and TUSFI may be the issuer in an offering of senior debt securities, as specified in the applicable prospectus supplement, and are collectively referred to as the “issuers” (and each, an “issuer”) in this prospectus. The terms “we,” “our” and “us” refer to the issuers.

Takeda’s audited consolidated financial statements as of March 31, 2024 and 2025, and for the fiscal years ended March 31, 2023, 2024 and 2025, which are incorporated by reference into this prospectus, have been prepared in accordance with International Financial Reporting Standards as issued by the International Accounting Standards Board (“IFRS”). The term IFRS also includes International Accounting Standards (“IAS”) and the related interpretations of the committees (Standard Interpretations Committee and International Financial Reporting Interpretations Committee). Unless otherwise stated or otherwise required by the context, Takeda’s financial statements are denominated in Japanese yen, the legal tender of Japan.

The terms “yen” or “¥” refer to Japanese yen, “$” refers to U.S. dollars and “EUR” or “€” refer to Euros, respectively. In this prospectus, any prospectus supplement and any free writing prospectus, yen figures and percentages have been rounded to the figures shown, unless otherwise specified. In tables and graphs with rounded figures, sums may not add up due to rounding.

<div align='center'>-1-</div>

### CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS
This prospectus, any prospectus supplement, any free writing prospectus and the information incorporated by reference in this prospectus include forward-looking statements regarding the intent, belief, current expectations and targets of our management